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Ricardo F. Muñoz1,4

ABSTRACT
Tobacco disparities persist among low-income smokers who seek
care from safety-net clinics. Many of these patients suffer from chronic illnesses
(CILs) that are associated with and exacerbated by smoking. The objective of the
current study was to examine the differences between safety-net patients with
and without CILs in terms of nicotine dependence and related factors (such as
depression, anxiety) and self-efficacy regarding ability to abstain from smoking.
METHODS Sixty-four low-income smokers who thought about or intended to
quit smoking were recruited from the San Francisco Health Network (SFHN)
and assessed for CILs, nicotine dependence, depression, anxiety, and smoking
abstinence self-efficacy. Four one-way analyses of variance were used to examine
the difference between those with and without CIL on the latter four variables.
RESULTS The CIL group had significantly higher anxiety (CIL: 8.0 ± 5.35; non-CIL:
4.44 ± 3.48; p=0.02) and tended to have higher nicotine dependence (CIL: 5.40
± 2.58; non-CIL: 3.88 ± 2.28; p=0.04). In the CIL group, nicotine dependence
was positively correlated with anxiety [r(62)=0.39; p<0.01] and negatively
correlated with smoking abstinence self-efficacy [r(62)= -0.38; p<0.01]. Both
depression (Spearman’s rho=0.39; p<0.01) and anxiety (Spearman’s rho=0.29;
p<0.05) were associated with total number of CIL categories.
CONCLUSIONS Safety-net patients who smoke and suffer from CILs may be suffering
from higher levels of anxiety and have less confidence in their ability to quit
smoking. Incorporating mood management and developing interventions that
increase a sense of self-efficacy for refraining from smoking may be necessary
to help low-income smokers quit smoking.
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INTRODUCTION
Tobacco-related disparities and health disparities
are strongly related; poverty, mental health, lower
education levels, and unemployment are associated
with high rates of smoking and in turn high rates of
chronic illness (CIL)1,2. Many low-income smokers

experience multiple medical, psychological, and social
needs and often seek care from safety-net hospitals
and clinics which are woefully under-resourced to
address these concerns3,4. Smokers belonging to
disadvantaged groups have higher rates of tobacco
use, are less likely to make a quit attempt and are
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less likely to successfully quit, which significantly
increases the risk for developing CILs5. Some factors
that may contribute to continued tobacco use within
this population include social determinants of health,
minority status, higher levels of nicotine addiction,
higher levels of stress, and co-occurring physical
diseases and mental health diagnoses 1,2,6. Higher
smoking rates amongst lower social strata have
persisted despite public health initiatives such as
tobacco price increases, smoke-free policies, or robust
tobacco control programs7.
Given the multiple medical, psychological, and
social needs that low-income smokers face, the
current study seeks to expand the literature on
factors that underlie smoking in an underserved, lowincome patient population. Exploring the underlying
mechanisms that influence and are related to smoking
behavior in low-income populations is crucial given
their potential to inform the development of new
interventions that are specific to the unique challenges
of this social strata. In addition, low-income smokers
who suffer from CILs are at significantly higher risk
for poor health outcomes8 and may exhibit different
underlying mechanisms associated with smoking
behavior compared to smokers without CILs. In
this study, we examined the differences between
safety-net patients with and without CILs in terms
of nicotine dependence and related factors (such as
depression, anxiety) and self-efficacy regarding the
ability to abstain from smoking.
Like smoking and social strata, mental disorders
also independently increase the risk for developing
CILs2. For instance, depression has been identified
as an independent and prognostic factor for
cardiovascular disease and cardiovascular incidents9.
Thus, smokers diagnosed with mental disorders
are disproportionately impacted by morbidity and
mortality 10. The disproportionality of this health
disparity is significant given that over one-third of
smokers suffer from serious psychological distress11.
Smokers diagnosed with mental disorders smoke more
cigarettes per day on average, are more dependent
on nicotine, experience greater withdrawal symptoms
during quit attempts, and have lower quit rates 12.
Moreover, most smokers who suffer from mental
illness do not receive mental health treatment and
have significantly lower quit rates in part because
these individuals are more likely to be unemployed

men with lower socioeconomic status (SES) and
education levels, compared to smokers who are able
to receive mental health treatment13.
The co-occurrence of smoking with other mental
health disorders (e.g. anxiety, depression) is common
and the incidence of one disorder occurring without
co-occurring symptomatology is rare14. Notably,
smoking prevalence rates increase with a greater
number of mental disorders. Rates range from
18% for those with no mental disorder to 61% for
those diagnosed with three or more mental health
disorders 10,15 . However, most of the literature
examining mental health disorders and smoking has
generally focused on a singular clinical disorder12,
resulting in a lack of knowledge regarding how to
address smoking cessation in populations that present
with multiple co-occurring mental health conditions16.
Prior research suggests that the presence of multiple
health risks, e.g. smoking, low SES, depression, has
a negative synergistic influence on morbidity and
mortality17. Hence, studying underlying mechanisms
that can influence behavior change across multiple
domains and that have the potential for increased
health benefits, is necessary. The facets of social
cognitive theory (SCT) have been widely used to
explain, identify, intervene and predict various factors
that are associated with health behaviors18. One facet
of SCT that has been shown to influence behavior
is self-efficacy, which is the perceived confidence
in one’s ability to perform specific behaviors in
varying contexts 18. For instance, self-efficacy has
been identified as a predictor of smoking behavior
and cessation19. Individuals who have a greater sense
of self-efficacy are able to abstain from smoking in
high-risk situations, e.g. when experiencing negative
affectivity and when being faced with situational cues,
such as being around other smokers, are more capable
of bouncing back from a slip as opposed to proceeding
to relapse18,20. The ability to modify self-efficacy has
made it an appropriate outcome measure following
smoking cessation interventions19. However, factors
that influence self-efficacy, e.g. CIL status, nicotine
dependence, depression and anxiety, and behavioral
change may vary between persons with and without
CIL.
According to SCT, smoking behaviors are
influenced by the reciprocal determinism of cognitive,
environmental, and behavioral factors21. These factors
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impact each other in a reciprocal manner meaning
that causal changes could begin at each factor and
the directionality of causation could involve many
possibilities21. For example, smoking could lead to a
CIL, which increases anxiety and depression, reduces
self-efficacy for abstinence, increases likelihood of
continuing to smoke, which then leads to more CILs
and so on. However, this causal change could begin
anywhere. For example, depression and anxiety
could lead to smoking, which could then lead to CILs
and so forth. Given that such a causal change has no
necessary first cause in all persons, exploring factors
that underly smoking behavior and utilizing that
information to intervene where we can in the chain
may be helpful in stopping the process.
Safety-net hospitals and clinics serve low-income
patients with a myriad of medical, psychological, and
social needs. Many of these patients smoke and suffer
from CILs3. Although low-income smokers suffer
disproportionately from health and tobacco related
disparities, tobacco use among this patient population
remains undertreated, understudied, and underrecognized as a problem1,3,13. To our knowledge, no
prior research has explored differences in factors
related to smoking – nicotine dependence, depression,
anxiety, smoking abstinence self-efficacy – between
low-income safety-net patients with and without CIL.
Our primary hypothesis was that compared to those
without CIL, participants with CIL would demonstrate
greater nicotine dependence, higher depression and
anxiety scores, and lower smoking-abstinence selfefficacy. In exploratory analyses, we also explored
correlations between our outcome variables, such as
nicotine dependence, depression, anxiety, smoking
abstinence self-efficacy and: 1) the number of CILs
in the two groups, and 2) each of six CIL categories
(cardiovascular and circulatory disease, respiratory
disease, endocrine disease, abdominal disease and
obesity, chronic pain, and other disease).

waiting rooms and other locations with the approval
of each of these sites. Staff at the various recruitment
sites were also given flyers to inform prospective
participants about the study. Eligible participants
were low-income, as defined by the poverty threshold
for San Francisco Bay Area residents22, adult (aged
≥18 years) tobacco smokers who have thought about
or intended to quit smoking within 30 days.

Measures
Demographic questionnaire
Participants reported their age, race, ethnicity,
gender, sexual orientation, marital status, employment
status, total household income, and years of education.
List of chronic illnesses
A self-report questionnaire asking for previous
year presence or absence of 22 CILs were used to
provide information on prevalence of CIL in the
study sample. This questionnaire was modeled after
the physical health self-report module in Atwoli et
al. 23. Similar to Atwoli et al.23, the 22 CILs were
then aggregated by type into six disease categories:
cardiovascular and circulatory disease (high blood
pressure, high cholesterol, heart attack, stroke,
heart disease), respiratory disease (asthma, seasonal
allergies, other lung disease), endocrine disease
(diabetes, thyroid, osteoporosis), abdominal disease
and obesity (acid reflux, ulcer, obesity), chronic
pain (arthritis, chronic pain, frequent headaches),
and other disease (neurological disease, epilepsy,
cancer, kidney disease, and other, to be specified by
the participant).
Depression
The Patient Health Questionnaire 9 (PHQ-9) is
a 9-item self-report questionnaire that assesses
depression symptoms and severity24. The PHQ-9
assesses depressive symptomatology for the past two
weeks. The questionnaire begins by asking ‘Over the
past 2 weeks how often have you been bothered by ...’
followed by items such as, ‘Little interest of pleasure
in doing things’ and ‘Feeling down, depressed, or
hopeless’. Possible scores range from 0 to 27, with
each of the 9 items scored from 0 (not at all) to 3
(nearly every day). Cut-off scores for the PHQ-9 in
screening positive for a major depressive episode have
ranged from 8–11. In this study, we used a cut-off

METHODS
Participants
Participants were recruited from safety-net primary
care clinics, within the San Francisco Health Network
(SFHN) and other sites in the San Francisco Bay Area,
that primarily serve low-income individuals such as
community resource centers and community mental
health clinics. Recruitment flyers were posted in
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score of ≥10 to categorize participants as screening
positive for a major depressive episode25.

The higher the score, the more self-efficacy one has
to abstain from smoking. The original SASEQ has
been shown to have high internal consistency with
a Cronbach’s alpha of 0.8928. Internal consistency
for the SASEQ that was used for this study yielded a
Cronbach’s alpha of 0.86.

Anxiety
The Generalized Anxiety Disorder 7 (GAD-7) is a
7-item self-report questionnaire that assesses anxiety
symptoms and severity 26. The GAD-7 measures
anxiety symptomatology for the past two weeks. The
questionnaire begins by initially asking: ‘Over the
past 2 weeks how often have you been bothered by
...’ followed by items such as ‘Trouble relaxing’ and
‘Worrying too much about different things’. Possible
scores range from 0 to 21, with each of the 7 items
scored from 0 (not at all) to 3 (nearly every day). In
this study, we used a cut-off score of ≥8 to categorize
a participant as screening positive for a diagnosable
generalized anxiety disorder25.

Procedure
Participants were recruited from Zuckerberg San
Francisco General Hospital (ZSFG), various clinics
within the SFHN, and other surrounding areas in
the San Francisco Bay Area that serve primarily lowincome individuals. All participants provided informed
consent, and study procedures were approved by the
University of California, San Francisco and Palo Alto
University. Data and analyses presented in the study
were from self-report questionnaires that participants
completed in-person at ZSFG on iPads.

Nicotine dependence
The Fagerström test of nicotine dependence (FTND)
is a 6-item self-report measure that assesses nicotine
dependence27. The measure includes items such as:
‘Do you smoke more frequently during the first hours
after waking than during the rest of the day?’. Possible
scores range from 0 to 10. A cut-off score of 6, the
gold standard for detecting high nicotine dependence,
was used in this study27.

Statistical analysis
Power estimates
An a priori power analysis was performed for sample
size estimation using G*Power (version 3.1.9.2)29. This
study was designed with adequate power for a oneway analysis of variance of our primary hypothesis,
namely participants with CIL will demonstrate greater
nicotine dependence, higher depression and anxiety
scores, and lower smoking-abstinence self-efficacy
compared to those without CIL. These calculations
indicate that a total sample size between 42 and 102
is required to detect a medium to large effect size
(Cohen’s d between 0.5 and 0.8) between those with
and without CIL. Given these power estimates, we
expected our study sample of 64 low-income smokers
to be appropriately powered to detect at least medium
effect sizes. The standard alpha level (0.05) for main
effects was adjusted for four multiple comparisons
using a modified Bonferroni method30. This approach
considers the mean correlation between outcome
variables and the number of tests in the adjustment of
alpha levels. We summed the intercorrelations among
our four outcome measures and divided the result by
the number of correlations used (average r=0.37).
This correlation along with the 4 comparisons was
used to derive an adjusted alpha level of p≤0.021
to determine statistical significance for the one-way
analysis of variance. We also report any findings of
our primary analysis that did not reach Bonferroni

Self-efficacy
The Smoking Abstinence Self-Efficacy Questionnaire
(SASEQ) is a 6-item self-report questionnaire used
to measure self-efficacy to refrain from smoking in
specific contexts28. After reviewing the SASEQ with
multiple researchers on the research team, it was
determined that modifying questions for clarity and
understanding, while not altering the content of
the questions, was the best course of action before
administering the measure as is. For example, one
of the questions the SASEQ asks includes: ‘You feel
agitated or tense. Are you confident that you will
not smoke?’. This question was reworded as: ‘How
confident are you that you will not smoke when you
feel agitated or tense?’. The original response items
for the SASEQ are on a 5-point Likert scale with
responses ranging from ‘Certainly’ to ‘Certainly not’.
The research team modified the responses for each
question to include a 0–10 slider scale to provide
more variability. Possible scores range from 0 to 60.
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correction but were less than the standard statistical
alpha of p<0.05 as trends towards significance. For
exploratory correlational analyses a standard level
p<0.05 was considered significant.

of 16 low-income smokers aged 24–59 years (41.69
± 10.86), 2 (12.5%) of which were female. Over twothirds (11 out of 16; 68.8%) of the non-CIL group
reported completing high school or less, and 12 out
of 16 (75%) reported making an annual income of
less than $20000.

Descriptive and statistical model analyses
All statistical analyses were performed using the
Statistical Package for Social Sciences (SPSS) version
2631. Demographic characteristics were compared
using independent samples t-tests for continuous
variables and the chi-squared test for categorical
variables. For our primary hypotheses, four oneway analyses of variance were used to examine the
difference between CIL group and those without
CIL (our independent variables) on our four primary
dependent variables: 1) smoking abstinence selfefficacy, 2) nicotine dependence, 3) depression, and
4) anxiety scores. Prior to analyses, dependent variable
normality was confirmed. In exploratory analyses,
we examined the associations between smoking
abstinence self-efficacy, depression, anxiety, nicotine
dependence, and the number of CIL categories
(among the CIL group). Correlations with CIL disease
categories were analyzed via Spearman correlations.
All other associations were examined with Pearson
correlations.

Table 1. Participant characteristics and group
comparisons, SFHN 2018 (N=64)
Characteristics

Non-CIL
group
(N=16)
n (%)

CIL group
(N=48)

2 (12.5)

19 (39.6)

14 (87.5)

28 (58.3)

0 (0.00)

1 (2.1)

n (%)

Gender
Female
Male
Transgender
Age (years) mean ± SD

41.69 ± 10.86 46.62 ± 10.07

Education years, mean ± SD

11.56 ± 2.53

12.43 ± 2.91

Black/African American

2 (12.5)

19 (39.6)

Asian

0 (0.0)

1 (2.1)

Mestizo

1 (6.3)

2 (4.2)

Native American/Alaskan Native

2 (12.5)

3 (6.3)

Native Hawaiian/Pacific Islander

1 (6.3)

1 (2.1)

White

6 (37.5)

14 (29.2)

Biracial

3 (18.8)

8 (16.7)

Unknown/Not reported

1 (6.3)

0 (0.0)

Latinx/Hispanic

6 (37.5)

10 (20.8)

Not Latinx/Hispanic

7 (43.8)

30 (62.5)

Unknown/Not reported

3 (18.8)

8 (16.7)

Full-time

4 (25)

2 (4.2)

Part-time

1 (6.3)

3 (6.3)

Retired

0 (0.00)

2 (4.2)

Student

1 (6.3)

7 (14.6)

10 (62.5)

34 (70.8)

Race

RESULTS
Participant characteristics
Descriptive statistics of participant characteristics
are presented in Table 1; there were no statistically
significant differences between the CIL group and
the non-CIL group. The total sample consisted of
64 low-income smokers, 48 (75%) of which had at
least one CIL. The CIL group included participants
who indicated that they had the presence of at least
one CIL. Characteristics consisted of 48 low-income
smokers, 19 out of 48 were female (39.6%) and 1
(2.1%) of which identified as transgender; the age
range for the CIL group was 31–70 years (46.64 ±
10.27). Over half of this group (31 out of 48; 64.6%)
reported having completed high school or less, and 39
out of 48 (81.3%) reported having an annual income
of less than $20000. Two-thirds (29 out of 48; 60.4%)
of the CIL group reported having CILs in two or more
of the CIL disease categories. The non-CIL group
included participants who indicated that they did not
have the presence of any CIL; characteristics consisted

Ethnicity

Employment status

Unemployed
Household income (US$)
<20000

12 (75)

39 (81.3)

20000–34999

0 (0.0)

5 (19.4)

35000–49999

2 (12.5)

1 (2.1)

50000–74999

1 (6.3)

1 (2.1)

75000–99000

1 (6.3)

1 (2.1)

Unknown/Not reported

0 (0.0)

1 (2.1)

CIL: chronic illness. There were no statistically significant differences between CIL
groups.
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Table 2. Nicotine dependence, depression, anxiety, and self-efficacy group comparisons, SFHN 2018 (N=64)
Non-CIL group
(N=16)
Mean ± SD

CIL group
(N=48)
Mean ± SD

3.88 ± 2.28

5.40 ± 2.58

5.13 ± 4.38

β

p

95% CI

-1.52

0.040**

(-2.97, -0.071)

7.69 ± 6.62

-2.56

0.154

(-6.11, 0.989)

4.44 ± 3.48

8.00 ± 5.59

-3.56

0.020*

(-6.54, -0.586)

25.13 ± 15.65

21.67 ± 12.74

3.46

0.378

(-4.33, 11.25)

Nicotine dependence
FTND total
Depression
PHQ-9 total
Anxiety
GAD-7 total
Self-efficacy
SASEQ total

CIL: chronic illness. *p<0.02 Bonferroni corrected. **p<0.05 indicating a trend towards significance. FTND: Fagerström test of nicotine dependence. PHQ-9: Patient Health
Questionnaire 9. GAD-7: Generalized Anxiety Disorder 7. SASEQ: Smoking Abstinence Self-Efficacy Questionnaire.

Group difference in nicotine dependence,
depression, anxiety, and self-efficacy by CIL status
A total of 15 participants (31.3%) in the CIL group
reported PHQ-9 scores ≥10, thus screening positive
for a major depressive episode compared to 3
(18.8%) in the non-CIL group (CIL: 7.69 ± 6.62;
non-CIL: 5.13 ± 4.38; p=0.154). The CIL group had
significantly higher anxiety scores compared to the
non-CIL group (CIL: 8.0 ± 5.35; non-CIL: 4.44 ±
3.48; p=0.02) with a total of 23 participants in the
CIL group (47.9%) having scores ≥8, thus screening
positive for a generalized anxiety disorder compared
to 3 (18.8%) in the non-CIL group. The CIL group
also had higher nicotine dependence but did not
reach significance given the significance level set
using the Bonferroni adjustment (CIL: 5.40 ± 2.58;
p=0.04); over half of the CIL group (52.1 %) reported
FTND scores ≥6 indicating high nicotine dependence
compared to the non-CIL group, in which 31.3%
reported FTND scores ≥6. Results depicting group
differences can be found in Table 2.

Table 3. Correlations in non-chronic illness group,
SFHN 2018 (N=16)
Measure

1

2

3

Nicotine dependence
1 FTND
Depression
2 PHQ-9

0.44

Anxiety
3 GAD-7

0.31

0.61*

0.17

-0.19

Smoking abstinence self-efficacy
4 SASEQ

-0.11

*p<0.05. FTND: Fagerström test of nicotine dependence. PHQ-9: Patient Health
Questionnaire 9. GAD-7: Generalized Anxiety Disorder 7. SASEQ: Smoking Abstinence
Self-Efficacy Questionnaire.

Table 4. Correlations in chronic illness group, SFHN
2018 (N=48)
Measure

1

2

3

4

Nicotine dependence
1 FTND
Depression
2 PHQ-9

Correlations between outcome variables and total
number of CILs within non-CIL and CIL groups
The correlational matrices for both non-CIL and CIL
groups are given in Table 3 and Table 4, respectively.
In the non-CIL group, anxiety was positively
correlated with depression [r(16)=0.61; p<0.05]. In
the CIL group, nicotine dependence was positively
correlated with anxiety [r(48)=0.39; p<0.01] and
negatively correlated with smoking abstinence selfefficacy [r(48)= -0.38; p<0.01]. Among the CIL

0.19

Anxiety
3 GAD-7

0.39**

0.69**

Smoking abstinence selfefficacy
4 SASEQ

-0.38** -0.14

-0.16

Chronic illness
5 Number of CIL categories

-0.09

0.39**

0.29*

-0.01

*p<0.05. **p<0.01. FTND: Fagerström test of nicotine dependence. PHQ-9: Patient
Health Questionnaire 9. GAD-7: Generalized Anxiety Disorder 7. SASEQ: Smoking
Abstinence Self-Efficacy Questionnaire.
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group, depression was also positively correlated with
anxiety [r(48)=0.69; p<0.01] and the total number
of CIL categories (Spearman’s rho=0.39; p<0.01).
Finally, anxiety was positively associated with the
total number of CIL categories (Spearman’s rho=0.29;
p<0.05) among the CIL group.

were positively correlated in each disease category:
cardiovascular and circulatory [r(21)=0.50; p<0.05],
respiratory [r(29)=0.64; p<0.01], abdominal
and obesity [r(20)=0.62; p<0.01], chronic pain
[r(22)=0.61; p<0.01], and other disease [r(10)=0.84;
p<0.01] apart from endocrine disease. Nicotine
dependence and smoking abstinence self-efficacy
were negatively correlated in cardiovascular and
circulatory disease [r(21)= -0.50; p<0.05] and
chronic pain [r(22)= -0.54; p<0.05]. Nicotine
dependence was positively correlated with anxiety in
respiratory disease [r(29)=0.49; p<0.01], chronic pain
[r(22)=0.58; p<0.01], and other disease [r(10)=0.67;
p<0.05].

Correlations between outcome variables and six
chronic illness categories
The correlational matrices for each chronic illness
category are given in Table 5. Anxiety and depression
Table 5. Correlations among different chronic illness
categories and outcome variables, SFHN 2018
Chronic
illness
category

Measure

1

Cardiovascular 1 Nicotine dependence
and circulatory 2 Depression
-0.50
disease (n=21)
3 Anxiety
0.31
4 Smoking abstinence
self-efficacy
Respiratory
1 Nicotine dependence
disease (n=29) 2 Depression
3 Anxiety
4 Smoking abstinence
self-efficacy
Endocrine
disease (n=6)

-0.50*

0.50*
0.01

0.04

0.78
0.49**
-0.25

0.64**
0.05

2 Depression

0.23

3 Anxiety

0.51

0.66

-0.15

0.29

Abdominal
1 Nicotine dependence
disease and
2 Depression
-0.04
obesity (n=20)
3 Anxiety
0.34
4 Smoking abstinence
self-efficacy

-0.13

-0.11

0.66

0.62**
-0.21

-0.08

1 Nicotine dependence
2 Depression
3 Anxiety
4 Smoking abstinence
self-efficacy

Other disease
(n=10)

DISCUSSION
This study examined the differences between
smokers with and without CILs in terms of nicotine
dependence, depression, anxiety, and smoking
abstinence self-efficacy. The goal of the study
was to gain a greater understanding of the factors
that influence smoking behavior in a population
that disproportionately suffers from morbidity and
mortality. We found that individuals who have CIL
exhibited higher anxiety scores and tended to be more
addicted to nicotine than those without CIL. Anxiety
was associated with higher nicotine dependence and
depression among the CIL group as well as those
with respiratory disease, chronic pain, and other
disease; depression and anxiety were both positively
associated with the number of CIL categories and
each disease category apart from endocrine disease.
Nicotine dependence was also negatively associated
with smoking abstinence self-efficacy among the CIL
group, in those with cardiovascular and circulatory
disease and in those with chronic pain. Among
smokers in the non-CIL group, anxiety was positively
correlated with depression.
The social determinants of health that contribute
to health disparities are linked to tobacco-related
disparities; smokers of disadvantaged groups have
higher levels of nicotine dependence and mental
health diagnoses both of which markedly increase
the risk for developing CILs5,6. We found significant
differences between groups on anxiety and notable
differences on nicotine dependence. In this study,
smokers with CIL reported higher levels of anxiety
and tended to be more addicted to nicotine compared

3

1 Nicotine dependence

4 Smoking abstinence
self-efficacy

Chronic pain
(n=22)

2

0.80
0.58**
-0.51*

0.61**
-0.03

-0.20

1 Nicotine dependence
2 Depression
3 Anxiety
4 Smoking abstinence
self-efficacy

0.35
0.67*
-0.54

0.84**
-0.22

-0.43

*p<0.05. **p<0.01.
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to smokers without CIL. These results are in
line with previous research which has found that
patients with CIL tend to experience higher levels
of anxiety and depression than those without32. One
possible explanation for higher levels of anxiety is
that smokers with CIL may be experiencing greater
anxiety because of their chronic conditions, as
individuals who cope with CIL commonly report
fears and stressors associated with illness symptoms
recurring and/or worsening33. Similarly, we found
that both depression and anxiety were related to
number of CIL categories and although there were
no significant differences between CIL and non-CIL
groups in terms of depression and anxiety, there were
more smokers in the CIL group who screened positive
for a major depressive episode and generalized
anxiety disorder. Thus, patients who suffer from one
or more CIL are more likely to experience anxiety and
depression. This finding is consistent with previous
research, indicating that coping with more than one
CIL is associated with an increase in the occurrence
of depression and anxiety34,35.
Anxiety and depression are common co-occurring
mental health diagnoses in smokers and those
with CIL36. Although smoking may exacerbate and
worsen symptoms of CILs, individuals with anxiety
and depression may be smoking more to cope with
their mental health symptoms which in turn increases
their nicotine dependence. Nicotine’s psychoactive
effects, which are associated with mood modulation
and the reduction of stress, make it increasingly
difficult for individuals to quit smoking despite it
being deleterious to their health37. Consistent with
previous studies38, this study showed that anxiety
is linked to nicotine dependence. Specifically, we
found that smokers in the CIL group with higher
nicotine dependence (FTND scores) had higher
anxiety symptoms (GAD-7 scores); likewise, we found
this association among those who indicated having
respiratory disease, chronic pain, and other forms of
disease. It may be important for clinicians to assess
for anxiety in smokers with CIL, especially in patients
who suffer from respiratory illnesses such as chronic
obstructive pulmonary disease (COPD) and chronic
pain. When providing smoking cessation treatment,
it is important to remember that anxiety may worsen
in patients who are attempting to quit smoking and
make provisions to provide treatment for anxiety as

well as appropriate psychosocial support to empower
successful quitting of smoking. It is also important
to routinely screen patients with CIL for anxiety and
depression during medical encounters. Future studies
are needed to evaluate whether routine assessment
and monitoring anxiety symptoms in CIL patients: a)
will improve health outcomes, and b) whether specific
anxiety-related interventions may improve smoking
cessation in low-income smokers who have CIL.
Among smokers with CIL, nicotine dependence
and smoking-abstinence self-efficacy were negatively
correlated; correspondingly, this association was also
found in those who indicated having cardiovascular
and circulatory disease and chronic pain. This
suggests that within this sample, individuals who are
more dependent on nicotine are also less confident
in their ability to abstain from smoking in high-risk
situations, e.g. when faced with situational cues or
when experiencing negative affectivity, because
of the cravings these situations induce, the desire
to relieve withdrawal symptoms, and the need to
regulate mood18,20,37. These findings are in line with
previous research indicating that individuals with a
lower sense of self-efficacy find it more difficult to
resist smoking in high-risk situations and are more
likely to relapse18,20. However, in this sample of lowincome smokers, this relationship only existed among
those who have CIL. This result reveals that smokers
who have a CIL may have a harder time quitting
smoking than those who do not. Understanding
how self-efficacy influences smokers who present
with multiple health risks is important because selfefficacy in one behavioral domain (e.g. smoking
cessation) may impact, e.g. increase or decrease, selfefficacy in other behavioral domains that influence
morbidity and mortality; for example, success in
quitting smoking may also increase one’s self-efficacy
to improve other modifiable health risks such as the
behaviors associated with depression17 which in turn
may increase CIL self-management and reduce the
susceptibility and severity of CILs.
Although previous studies have highlighted the
need for clinicians to promote a sense of confidence
in a smoker’s abilities to abstain from smoking39,
few treatments are designed to improve self-efficacy
despite many studies stressing the need for these
interventions20. However, this clinical implication
must be adapted and applied appropriately to low-
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income populations who suffer from multiple cooccurring diseases/disorders. Given the complexities
involved in treating low-income smokers who also
have CILs and may be suffering from mental disorders,
future research is needed in developing intensive
interdisciplinary smoking cessation interventions
with a focus on CIL symptom self-management,
coping strategies for managing distress in triggering
situations, and confidence-building. While many
hospital systems provide smoking cessation resources,
a continued emphasis must be placed on offering
low-cost or free resources (such as free smoking
cessation apps), nicotine replacement therapies
(NRTs), individual and/or group psychotherapy,
and pharmacologic aids. Understanding that this
population requires more support for quitting given
their socioeconomic status and multiple morbidities,
hospital systems and community clinics should obtain
the resources necessary to support these patients
and implement quality improvement (QI) initiatives
to determine whether providing these resources
improves abstinence rates and chronic disease
management.

who are not involved in treatment or connected to
care may have differing levels of motivation to quit
as well as differing levels of mental health and selfefficacy. For example, low-income smokers who are
not treatment seeking may have little motivation to
quit despite having a CIL diagnosis. Fifth, while the
study’s outcomes may be associated with a lower
likelihood of smoking cessation, this study did not
measure smoking cessation directly. Within this
selected sample of low-income smokers, there may
have been other factors that contribute to smoking
cessation such as previous quit attempts that were
not measured. Sixth, given the voluntary nature of
this study, results presented cannot be generalized
to those who chose not to participate. Similarly, the
data presented here are from a low-income population
in an urban area of the United States, the results
may not generalize to other low-income populations
who reside in rural areas or areas outside the United
States. Nevertheless, this research contributes to a
body of literature in a low-income population that has
historically been understudied and found that lowincome smokers with CIL may need more intensive
cessation treatments since they exhibit characteristics
that may make it more difficult to quit smoking5,13.
Future research in this area is warranted. Lowincome smokers with CILs need to receive adequate
smoking cessation treatments. Given the multiple
co-occurring diseases/disorders that low-income
smokers experience, comprehensive interdisciplinary
treatments are needed. Additionally, future research
should include a qualitative component to gain a
better understanding of the internal and external
challenges that low-income smokers face when they
decide to quit smoking.
Although routine screening occurs in some large
healthcare systems3, the following recommendations
should be implemented to reduce the number of lowincome patients with CILs that are tobacco related:
1) routine screening for smoking, depression, and
anxiety; 2) providing smoking cessation interventions
that include mood management interventions; and 3)
developing interventions that increase a sense of selfefficacy for refraining from smoking.

Limitations
This study has some limitations. First, the crosssectional and self-report nature of the research design
does not allow for causal interpretations of the results.
Although number of CILs were related to both anxiety
and depression in smokers, the bidirectionality of
these relationships limits our ability to interpret
their etiological nature and thus, limits our ability to
provide preventative clinical implications. Similarly,
although we were able to garner meaningful insights
into factors that are associated with smoking cessation
in a low-income population, we were not able to
measure changes through time. Second, an inclusion
criterion consisted of whether participants had
thought about or intended to quit smoking in 30 days;
this criterion may have captured smokers at differing
levels of motivation which could have influenced
self-efficacy outcomes. Third, the study had a
relatively small sample size which affected statistical
power and limited our ability to run more robust
analyses. Fourth, this sample is limited to low-income
smokers who use a public sector healthcare system. CONCLUSIONS
It is possible that this sample may represent only Research consistently shows that low-income smokers
treatment seeking low-income smokers. Individuals suffer disproportionately from tobacco-related
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disparities and have a higher risk for morbidity and
mortality1–4. Therefore, it is important to gain a greater
understanding of the factors that underlie smoking
in marginalized populations. In this study, relative
to smokers who do not have chronic illness (CIL),
smokers with CIL reported higher levels of anxiety
and tended to be more addicted to nicotine; among
those with CIL, nicotine dependence and self-efficacy
were related. Assessing for anxiety and depression
and incorporating mood management interventions
with self-efficacy components may be necessary to
help low-income smokers quit.
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